静脉注射伏立康唑在原发性免疫缺陷婴儿和儿童中的治疗药物监测。
Therapeutic drug monitoring of voriconazole after intravenous administration in infants and children with primary immunodeficiency.
机构信息
Université Paris Descartes, Assistance Publique-Hôpitaux de Paris, Paris, France.
出版信息
Ther Drug Monit. 2011 Aug;33(4):464-6. doi: 10.1097/FTD.0b013e3182241b2b.
OBJECTIVE
A voriconazole trough concentration (Ctrough) <1 mg/L is associated with a higher risk of treatment failure. The aim of this work was to describe the probability of not achieving this target concentration in infants and children receiving intravenous voriconazole.
METHODS
Voriconazole trough concentrations obtained during routine therapeutic drug monitoring over a 5-year period were collected retrospectively from infants and children receiving intravenous voriconazole for presumed or proven invasive fungal infections.
RESULTS
Sixty-two trough concentrations were obtained from 6 infants and 10 children. The risk of a Ctrough <1 mg/L was 77% and 47%, respectively. Daily doses between 20 and 32 mg/kg were necessary in some patients to achieve a Ctrough >1 mg/L, compared with the currently recommended 14-mg/kg regimen.
CONCLUSIONS
Routine therapeutic drug monitoring is potentially helpful in infants and children receiving voriconazole, even intravenously.
目的
伏立康唑谷浓度（Ctrough）<1 毫克/升与治疗失败的风险较高相关。本研究旨在描述接受静脉用伏立康唑治疗的婴儿和儿童无法达到这一目标浓度的概率。
方法
本研究回顾性收集了在过去 5 年中接受静脉用伏立康唑治疗疑似或确诊侵袭性真菌感染的婴儿和儿童的常规治疗药物监测中的伏立康唑谷浓度。
结果
从 6 名婴儿和 10 名儿童中获得了 62 个谷浓度值。Ctrough<1 毫克/升的风险分别为 77%和 47%。与目前推荐的 14 毫克/公斤方案相比，一些患者需要每天给予 20 至 32 毫克/公斤的剂量才能达到 Ctrough>1 毫克/升。
结论
即使是静脉内给予伏立康唑，常规治疗药物监测在婴儿和儿童中也具有潜在的帮助。
Zotero 插件